Louisiana State Employees Retirement System Makes New $648,000 Investment in Xencor, Inc. (NASDAQ:XNCR)

Louisiana State Employees Retirement System bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 30,500 shares of the biopharmaceutical company’s stock, valued at approximately $648,000. Louisiana State Employees Retirement System owned approximately 0.05% of Xencor at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. AE Wealth Management LLC acquired a new position in shares of Xencor in the third quarter valued at approximately $502,000. SG Americas Securities LLC acquired a new position in shares of Xencor in the third quarter valued at approximately $875,000. Raymond James Financial Services Advisors Inc. increased its stake in shares of Xencor by 4.5% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 16,781 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 718 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Xencor by 24.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,575 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 2,431 shares during the period. Finally, BluePath Capital Management LLC acquired a new position in shares of Xencor in the third quarter valued at approximately $31,000.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on XNCR shares. Piper Sandler reissued a “neutral” rating and set a $24.00 target price (down previously from $37.00) on shares of Xencor in a research report on Wednesday, February 28th. Mizuho decreased their target price on shares of Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, January 22nd. Wedbush decreased their target price on shares of Xencor from $36.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. BMO Capital Markets decreased their target price on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Finally, BTIG Research decreased their target price on shares of Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, April 16th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Insider Buying and Selling

In related news, VP John R. Desjarlais sold 54,108 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the transaction, the vice president now directly owns 161,675 shares in the company, valued at approximately $3,133,261.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, VP John R. Desjarlais sold 54,108 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the transaction, the vice president now directly owns 161,675 shares in the company, valued at approximately $3,133,261.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kurt A. Gustafson sold 14,000 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $23.18, for a total value of $324,520.00. Following the completion of the sale, the director now directly owns 6,007 shares of the company’s stock, valued at $139,242.26. The disclosure for this sale can be found here. Insiders have sold a total of 101,351 shares of company stock worth $2,152,417 in the last ninety days. Corporate insiders own 4.97% of the company’s stock.

Xencor Price Performance

Xencor stock opened at $19.98 on Monday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -9.51 and a beta of 0.76. Xencor, Inc. has a 52-week low of $16.49 and a 52-week high of $28.96. The stock’s 50 day moving average price is $22.02 and its two-hundred day moving average price is $20.36. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.36 and a current ratio of 7.36.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.67). Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. The business had revenue of $44.70 million for the quarter, compared to the consensus estimate of $77.63 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. Xencor’s quarterly revenue was up 106.9% on a year-over-year basis. On average, equities analysts predict that Xencor, Inc. will post -3.25 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.